Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jesse Price

Physician Assistant, Medical Mt Pleasant, SC Physician Assistant

NPI 1093091761 CMS profile 11163048

180 Wingo Way, Suite 306, Mt Pleasant, SC 29464

Open in the dashboard

General payments

$5,592

302 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jesse Price of Mt Pleasant, SC is reported in the CMS Open Payments database as having received $5,592 across 302 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,145 61
2024 General $1,382 65
2023 General $527 27
2022 General $797 47
2021 General $1,742 102

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jesse Price
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Jesse Price were reported at $1,145. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Jesse Price Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,742 $156 $41–$563 $132
2022 $797 $185 $55–$649 $149
2023 $527 $199 $58–$717 $160
2024 $1,382 $206 $62–$740 $164
2025 $1,145 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Pfizer Inc. $662 36 payments
  2. Novo Nordisk Inc $621 34 payments
  3. AbbVie, Inc. $439 30 payments
  4. Amgen Inc. $438 27 payments
  5. Lilly USA, LLC $387 20 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $295 17 payments
  7. E.R. Squibb & Sons, L.L.C. $261 10 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $206 11 payments
  9. GlaxoSmithKline, LLC. $198 6 payments
  10. Novartis Pharmaceuticals Corporation $169 9 payments
  11. Other $1,917 102 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,592 302 payments
Products named General payments · program years 2021–2025
  1. Ozempic $382 21 payments
  2. RYBELSUS $382 21 payments
  3. XIFAXAN $295 17 payments
  4. NURTEC ODT $289 15 payments
  5. MOUNJARO $264 13 payments
  6. ELIQUIS Cardiovascular $261 10 payments
  7. ELIQUIS Cardiovascular;Metabolic Disease $224 12 payments
  8. COMIRNATY $216 11 payments
  9. PREVNAR 20 $205 11 payments
  10. ABRYSVO $179 9 payments
  11. Other $4,972 280 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 81 drugs

Part D claims

2,948

Median for Physician Assistant: 241

Drug cost

$156,165

Median for Physician Assistant: $4,110

Branded share of claims

15.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 43 $49,692
Farxiga Dapagliflozin Propanediol Brand 27 $21,631
Ozempic Semaglutide Brand 19 $20,249
Mounjaro Tirzepatide Brand 13 $14,886
Creon Lipase/Protease/Amylase Brand 12 $10,384
Rosuvastatin Calcium Generic 182 $2,709
Levothyroxine Sodium Generic 180 $2,302
Atorvastatin Calcium Generic 205 $2,276
Ezetimibe Generic 42 $1,903
Bupropion Xl Bupropion Hcl Brand 34 $1,664

The 10 drugs with the highest cost, of 81 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$36,661

Of which drugs: $1,641

Medicare patients

345

Average age 75

Services billed

688

233 women, 112 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 51%
Ischemic heart disease 22%
Atrial fibrillation 21%
Depression 21%
Diabetes 20%
Cancer 20%
Osteoporosis 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AREXVY
  • GlaxoSmithKline, LLC. $121
$121 — —
IBSRELA
  • Ardelyx, Inc. $114
$114 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $107
$107 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $99
$99 — —
RYBELSUS
  • Novo Nordisk Inc $93
$93 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

302 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record